DGIdb - DECITABINE Drug Record

DECITABINE chembl:CHEMBL1201129 ApprovedAntineoplasticImmunotherapy

Alternate Names:

NSC-127716
DACOGEN
DECITABINE
DAC
DACOGEN®
AZADC
5-AZADEOXYCYTIDINE
4-AMINO-1-(2-DEOXY-BETA-D-ERYTHRO-PENTOFURANOSYL)-S-TRIAZIN-2(1H)-ONE
rxcui:15657
chemidplus:2353-33-5
drugbank:01262
pubchem.compound:451668
chembl:CHEMBL1201129

Drug Info:

Drug Class	antineoplastic agents
Year of Approval	2006
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent

(7 More Sources)

Publications:

Lou et al., 2014, Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells., PLoS ONE
Turcan et al., 2013, Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine., Oncotarget
Saba et al., 2005, Decitabine in myelodysplastic syndromes., Semin. Hematol.
Daskalakis et al., 2010, Decitabine., Recent Results Cancer Res.
Ando et al., 2000, Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells., Leukemia
Saunthararajah et al., 2003, Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease., Blood
Jabbour et al., 2008, Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies., Cancer
Karpf et al., 2001, Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine., Mol. Pharmacol.
Stresemann et al., 2008, Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine., Int. J. Cancer
Csankovszki et al., 2001, Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation., J. Cell Biol.
Oki et al., 2007, Decitabine--bedside to bench., Crit. Rev. Oncol. Hematol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Takebayashi et al., 2001, 5-Aza-2'-deoxycytidine induces histone hyperacetylation of mouse centromeric heterochromatin by a mechanism independent of DNA demethylation., Biochem. Biophys. Res. Commun.
Stewart et al., 2015, KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine., Cancer Res.
Bakker et al., 2002, Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells., J. Biol. Chem.
Zhong et al., 2002, Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas., Clin. Cancer Res.
Coombs et al., 2016, Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia., Haematologica
Metzeler et al., 2012, DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia., Leukemia
Bejar et al., 2014, TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients., Blood
Gratchev et al., 2001, Regulation of the intestinal mucin MUC2 gene expression in vivo: evidence for the role of promoter methylation., Cancer Lett.
Forrest et al., 2005, Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?, Transpl. Immunol.

DECITABINE DNMT3A

Interaction Score: 7.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type predicted – sensitive

Approval Status Clinical Study

PMIDs:
27418649 22124213

Sources:
JAX-CKB ChemblInteractions CIViC
DECITABINE ASXL1

Interaction Score: 5.62

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm

Response Type sensitive

Approval Status Clinical Study

PMIDs:
25224413

Sources:
JAX-CKB
DECITABINE MUC2

Interaction Score: 3.75

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11368880

Sources:
NCI
DECITABINE TET2

Interaction Score: 3.75

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm

Response Type sensitive

Approval Status Clinical Study

PMIDs:
25224413

Sources:
JAX-CKB
DECITABINE DNMT1

Interaction Score: 3.33

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction DNA (cytosine-5)-methyltransferase 1 inhibitor

Direct Interaction yes

Trial Name Dacogen/decitabine

PMIDs:
16015501 20072836 11069027 12907443 18398832 11259619 18425818 11352938 17023173 11752352 11688997 25968887

Sources:
TdgClinicalTrial ChemblInteractions TEND CIViC
DECITABINE IL2RA

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15814281

Sources:
NCI
DECITABINE GSTP1

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11960994 11948118

Sources:
NCI
DECITABINE KRAS

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25968887

Sources:
CIViC
DECITABINE EGFR

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
24874286

Sources:
JAX-CKB
DECITABINE IDH1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type oligodendroglioma

Response Type sensitive

Approval Status Preclinical - Pdx & cell culture

PMIDs:
24077826

Sources:
JAX-CKB
DECITABINE GMNN

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: DECITABINE
- Version: 01-August-2011
Alternate Names:

DECITABINE Primary Drug Name

Drug Info:

Year of Approval 2006

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: DECITABINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:
NCI: DAC
- Version: 14-September-2017
Alternate Names:

C981 NCI drug code

Drug Info:

Publications:

Forrest et al., 2005, Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?, Transpl. Immunol.

NCI: 5-AZADEOXYCYTIDINE

Version: 14-September-2017

Alternate Names:

C981 NCI drug code

Drug Info:

Publications:

Zhong et al., 2002, Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas., Clin. Cancer Res.

Bakker et al., 2002, Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells., J. Biol. Chem.

Gratchev et al., 2001, Regulation of the intestinal mucin MUC2 gene expression in vivo: evidence for the role of promoter methylation., Cancer Lett.

JAX-CKB: Decitabine

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Bejar et al., 2014, TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients., Blood

Lou et al., 2014, Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells., PLoS ONE

Coombs et al., 2016, Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia., Haematologica

CIViC: DECITABINE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Metzeler et al., 2012, DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia., Leukemia

Stewart et al., 2015, KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine., Cancer Res.

TTD: Decitabine
- Version: 2020.06.01
Alternate Names:

D0X5XU TTD Drug ID

Drug Info:

Publications:
DTC: DECITABINE
- Version: 02-September-2020
Alternate Names:

CHEMBL1201129 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201129
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: DECITABINE
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201129
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	acute myeloid leukemia
Response Type	predicted – sensitive
Approval Status	Clinical Study

Indication/Tumor Type	myelodysplastic/myeloproliferative neoplasm
Response Type	sensitive
Approval Status	Clinical Study

Mechanism of Interaction	DNA (cytosine-5)-methyltransferase 1 inhibitor
Direct Interaction	yes
Trial Name	Dacogen/decitabine

Evidence Type	Actionable
Approval Status	Preclinical
Response Type	sensitive

Indication/Tumor Type	oligodendroglioma
Response Type	sensitive
Approval Status	Preclinical - Pdx & cell culture

DECITABINE Drug Record

DECITABINE chembl:CHEMBL1201129 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type acute myeloid leukemia Response Type predicted – sensitive Approval Status Clinical Study

PMIDs: 27418649 22124213

Sources: JAX-CKB ChemblInteractions CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm Response Type sensitive Approval Status Clinical Study

PMIDs: 25224413

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11368880

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm Response Type sensitive Approval Status Clinical Study

PMIDs: 25224413

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction DNA (cytosine-5)-methyltransferase 1 inhibitor Direct Interaction yes Trial Name Dacogen/decitabine

PMIDs: 16015501 20072836 11069027 12907443 18398832 11259619 18425818 11352938 17023173 11752352 11688997 25968887

Sources: TdgClinicalTrial ChemblInteractions TEND CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15814281

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11960994 11948118

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25968887

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical Response Type sensitive

PMIDs: 24874286

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type oligodendroglioma Response Type sensitive Approval Status Preclinical - Pdx & cell culture

PMIDs: 24077826

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: DECITABINE

Alternate Names: DECITABINE Primary Drug Name

Drug Info: Year of Approval 2006 Drug Class antineoplastic agents

Publications:

TdgClinicalTrial: DECITABINE

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small Molecule FDA Approval approved

Publications:

NCI: DAC

Alternate Names: C981 NCI drug code

Drug Info:

Publications: Forrest et al., 2005, Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?, Transpl. Immunol.

NCI: 5-AZADEOXYCYTIDINE

Alternate Names: C981 NCI drug code

Drug Info:

JAX-CKB: Decitabine

Alternate Names:

Drug Info:

CIViC: DECITABINE

Alternate Names:

Drug Info:

Publications: Metzeler et al., 2012, DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia., Leukemia Stewart et al., 2015, KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine., Cancer Res.

TTD: Decitabine

Alternate Names: D0X5XU TTD Drug ID

Drug Info:

Publications:

DTC: DECITABINE

Alternate Names: CHEMBL1201129 ChEMBL Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1201129

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type predicted – sensitive

Approval Status Clinical Study

PMIDs:
27418649 22124213

Sources:
JAX-CKB ChemblInteractions CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm

Response Type sensitive

Approval Status Clinical Study

PMIDs:
25224413

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
11368880

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm

Response Type sensitive

Approval Status Clinical Study

PMIDs:
25224413

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction DNA (cytosine-5)-methyltransferase 1 inhibitor

Direct Interaction yes

Trial Name Dacogen/decitabine

PMIDs:
16015501 20072836 11069027 12907443 18398832 11259619 18425818 11352938 17023173 11752352 11688997 25968887

Sources:
TdgClinicalTrial ChemblInteractions TEND CIViC

Interaction Types & Directionality:

n/a

PMIDs:
15814281

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11960994 11948118

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25968887

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
24874286

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type oligodendroglioma

Response Type sensitive

Approval Status Preclinical - Pdx & cell culture

PMIDs:
24077826

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

DECITABINE Primary Drug Name

Drug Info:

Year of Approval 2006

Drug Class antineoplastic agents

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C981 NCI drug code

Publications:

Forrest et al., 2005, Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?, Transpl. Immunol.

Alternate Names:

C981 NCI drug code

Publications:

Metzeler et al., 2012, DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia., Leukemia

Stewart et al., 2015, KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine., Cancer Res.

Alternate Names:

D0X5XU TTD Drug ID

Alternate Names:

CHEMBL1201129 ChEMBL Drug ID